Publicaciones - IR Sant Pau

Buscar

01/01/2026 EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis

Marzo-Ortega, H, Harrison, SR, Fragoulis, GE, Michelena, X, Macía-Villa, C, Aydin, SZ, Balanescu, A, Bertheussen, H, Bundy, C, Chimenti, MS, Gisondi, P, Glintborg, B, Gossec, L, Kalyoncu, U, Lubrano, E, Nagy, G, Wagenaar, W, Puig, L, Queiro, R, Rahman, P, Shumnalieva, R, Soriano, ER, van den Bosch, F, Sande, MMGHV, Sepriano, A, Machado, PM, Siebert, S. EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. ANNALS OF THE RHEUMATIC DISEASES. 2026; 85(1)DOI:10.1016/j.ard.2025.10.002. PMID:41168056. IF:20.600(Q1/1D).

01/12/2025 ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa

Grau-Pérez, M, Ciudad, C, Molina-Leyva, A, Martorell, A, Vilarrasa, E, Albert, I, Garcias-Ladaria, J, Melgosa, FJ, Rivera, R, Campos, M, Haselgruber, S, Ochando, G, Pascual, JC, García-Ruiz, R, Alfageme, F. ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa. DERMATOLOGY. 2025; 241(5-6)DOI:10.1159/000546647. PMID:40587963. IF:2.700(Q2/4D).

01/12/2025 REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS

Ferrer, AL, Belinchón, I, Serra, MC, Clua, MG, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

01/12/2025 UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS

Ferrer, AL, Belinchón, I, Serra, MC, Martínez, LE, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

01/12/2025 HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS

Strober, B, Puig, L, Lebwohl, MG, Lakshminarasimhan, B, Khan, SA, Pillai, N, Kappelhoff, B, Weatherill, A, Warren, RB. HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

01/11/2025 Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) still be part of the Baseline Series?

Fernández, CPH, Borrego, L, Arnau, AMG, Sánchez, TS, Carrillo, JMC, Ninet, VZ, Baldrich, ES, Miquel, FJM, Salvador, JFS, Guijarro, SC, Gilo, AS, García, PM, Triviño, FN, Romero, FT, Serna, MR, Ninot, GM, González, IR, de la Fuente, EG, Nieto, MAP, Guillén, PSP, Pérez, JS, Rodríguez, JJP, Ortega, MEG, Pérez, RG, Doval, IG, Descalzo, MAG. Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) still be part of the Baseline Series?. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2024.10.063. PMID:40024601. IF:(Q/D).

01/09/2025 Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series

Mateu-Arrom, L, Martin, R, Expósito-Serrano, V, Alvarez-Abella, A, Serra-Baldrich, E, Spertino, J. Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.05.022. PMID:40480489. IF:(Q/D).

01/09/2025 Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups

Feldman, SR, Sanz, LP, Girolomoni, G, Jo, SJ, Jung, H, Jung, J. Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).

01/09/2025 Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials

Lebwohl, M, Langley, RG, Strober, B, Thaçi, D, Armstrong, A, Gordon, KB, Puig, L, Davies, O, Peterson, L, Davis, L, Warren, RB. Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).

01/07/2025 Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study

Ceravalls, J, Giménez-Arnau, AM, Exposito-Serrano, V, Chico, NF, Moya, AL, Bielsa, I, Ribó, P, Mascaró-Hereza, B, Bonfill-Orti, M, Spertino, J, Serra, E, Baliu-Piqué, C, Melé-Ninot, G. Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study. Actas Dermo-Sifiliograficas. 2025; 116(7)DOI:10.1016/j.ad.2024.08.014. PMID:. IF:(Q/D).

01/06/2025 Surgical Approach to Hidradenitis Suppurativa

Mateu-Arrom, L, Puig, L, Vilarrasa, E. Surgical Approach to Hidradenitis Suppurativa. Actas Dermo-Sifiliograficas. 2025; 116(6)DOI:10.1016/j.ad.2024.10.061. PMID:40185225. IF:(Q/D).

01/06/2025 Bimekizumab clinical efficacy in impactful body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods

Smith, A, Armstrong, AW, Elewski, B, Rich, P, Augustin, M, Carrascosa, JM, Vender, R, Lambert, J, Pinto, JML, Hoepken, B, Kavanagh, S, Puig, L. Bimekizumab clinical efficacy in impactful body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods. AUSTRALASIAN JOURNAL OF DERMATOLOGY. 2025; 66DOI:. PMID:. IF:1.800(Q3/6D).

01/04/2025 Real-world Efficacy of Brodalumab in Patients with moderate to severe Plaque Psoriasis, in Patients with BMI>30 and BMI=30, BROACTIVE: 2-year Results

Escalas, J, Armesto, S, Abalde, T, Blanco, IR, Blanco, MR, Herrera-Acosta, E, Puig, L, Morales, AM, Ferrán-Farrés, M, Auhage, E, Ribera, M. Real-world Efficacy of Brodalumab in Patients with moderate to severe Plaque Psoriasis, in Patients with BMI>30 and BMI=30, BROACTIVE: 2-year Results. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2025; 23DOI:. PMID:. IF:3.800(Q1/2D).

01/04/2025 Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis

Thaçi, D, Puig, L, Papp, K, Gold, LS, Fernández-Peñas, P, Huang, YH, Dossenbach, M, Falques, M, Agell, H, Schönherr, F, Vestergaard, C. Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2025; 23DOI:. PMID:. IF:3.800(Q1/2D).

01/01/2025 EFFECTIVENESS OF 12-MONTHS TRALOKINUMAB TREATMENT IN 124 ADULTS WITH ATOPIC DERMATITIS WITH GENITAL INVOLVEMENT: FINAL REAL-WORLD DATA FROM THE PROSPECTIVE, NON-INTERVENTIONAL, INTERNATIONAL, SINGLE-COHORT TRACE STUDY

Ameen, A, Serra-Baldrich, E, Arm-Strong, A, Festini, T, Vinther, F, Vittrup, I, Wiseman, MC. EFFECTIVENESS OF 12-MONTHS TRALOKINUMAB TREATMENT IN 124 ADULTS WITH ATOPIC DERMATITIS WITH GENITAL INVOLVEMENT: FINAL REAL-WORLD DATA FROM THE PROSPECTIVE, NON-INTERVENTIONAL, INTERNATIONAL, SINGLE-COHORT TRACE STUDY. ACTA DERMATO-VENEREOLOGICA. 2025; 105DOI:. PMID:. IF:3.700(Q1/2D).

12/01/2024 Student survey after ten years of continuous blended teaching of echocardiography.

Parra VM, Fita G, Azqueta M, González M, Aranda F, Maestre M, Silva J, Hortal J, Morales D, Bórquez E, Adasme F, Real MI, Mercadal J, Zelada P, Riobó G, Galdames K, Domenech RJ. Student survey after ten years of continuous blended teaching of echocardiography.. Revista Espanola De Anestesiologia Y Reanimacion. 2024; 71(1)DOI:10.1016/j.redare.2023.05.004. PMID:37683971. IF:(Q/D).

01/12/2023 Prediction of Acute Myocardial Injury in Noncardiac Surgery in Patients at Risk for Major Adverse Cardiovascular and Cerebrovascular Events: A Multivariable Risk Model.

Mases A, Beltrán de Heredia S, Gallart L, Román L, Bosch L, Núñez M, Rueda M, Recasens L, Sabaté S. Prediction of Acute Myocardial Injury in Noncardiac Surgery in Patients at Risk for Major Adverse Cardiovascular and Cerebrovascular Events: A Multivariable Risk Model.. ANESTHESIA AND ANALGESIA. 2023; 137(6)DOI:10.1213/ANE.0000000000006469. PMID:37043386. IF:4.600(Q1/2D).

26/08/2023 Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II).

Llau JV, Aldecoa C, Guasch E, Marco P, Marcos-Neira P, Paniagua P, Páramo JA, Quintana M, Rodríguez-Martorell FJ, Serrano A. Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II).. Revista Espanola De Anestesiologia Y Reanimacion. 2023; 70(7)DOI:10.1016/j.redare.2023.08.001. PMID:37640281. IF:(Q/D).

01/08/2023 Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II).

Llau JV, Aldecoa C, Guasch E, Marco P, Marcos-Neira P, Paniagua P, Páramo JA, Quintana M, Rodríguez-Martorell FJ, Serrano A. Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II).. Medicina Intensiva. 2023; 47(8)DOI:10.1016/j.medine.2023.03.019. PMID:37536911. IF:(Q/D).

01/07/2023 Clinical impact of the suspension of the ERAS protocol on patients undergoing radical cystectomy during the COVID-19 pandemic.

Castellarnau S, Gaya JM, Espinosa J, Sierra P, Huguet J, Palou J, Hernando D, Sabaté S, Breda A. Clinical impact of the suspension of the ERAS protocol on patients undergoing radical cystectomy during the COVID-19 pandemic.. Actas Urologicas Espanolas. 2023; 47(6)DOI:10.1016/j.acuroe.2023.01.006. PMID:36842706. IF:(Q/D).